We read with interest the TriNetX analysis by Halimi et al., which showed that hsCRP ≥2 mg/L was associated with higher risks of major cardiovascular events and death in CKD, and with a borderline higher risk of ESKD in the diabetes subgroup 1. The cardiovascular findings are noteworthy. We wonder, however, whether the renal conclusion would benefit from more cautious framing.
Wang et al. (Fri,) studied this question.